The islet autoantibody titres: Their clinical relevance in latent autoimmune diabetes in adults (LADA) and the classification of diabetes mellitus

Diabetic Medicine

Volumn 25, Issue 2, 2008, Pages 117-125

  Van Deutekom, A W ^a   Heine, R J ^a   Simsek, S ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Glutamic acid decarboxylase; Islet cell cytoplasmic autoantibodies; Latent autoimmune diabetes in adults; Type 1 diabetes; Type 2 diabetes

Indexed keywords

AUTOANTIBODY; C PEPTIDE; GLUTAMATE DECARBOXYLASE; INSULIN;

ANTIBODY DETECTION; ANTIBODY TITER; AUTOIMMUNE DISEASE; BODY MASS; CELL FUNCTION; COMPARATIVE STUDY; DIABETES MELLITUS; DIAGNOSTIC VALUE; DIET RESTRICTION; DISEASE CLASSIFICATION; DYSLIPIDEMIA; GENOTYPE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LATENT AUTOIMMUNE DIABETES IN ADULT; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; POPULATION RESEARCH; PREVALENCE; REVIEW; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE;

ADULT; AUTOANTIBODIES; BODY MASS INDEX; C-PEPTIDE; DIABETES MELLITUS, TYPE 1; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; ISLETS OF LANGERHANS; MALE; MIDDLE AGED;

EID: 39749160476     PISSN: 07423071     EISSN: 14645491     Source Type: Journal    
DOI: 10.1111/j.1464-5491.2007.02316.x     Document Type: Review

References (95)

1. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006 29 : S43 S48.
2. Gale EA. The discovery of Type 1 diabetes. Diabetes 2001 50 : 217 226.
3. Kuzuya T, Nakagawa S, Satoh J, Kanazawa Y, Iwamoto Y, Kobayashi M et al. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. Diabetes Res Clin Pract 2002 55 : 65 85.
4. Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 15 : 539 553.
5. Franke B, Galloway TS, Wilkin TJ. Developments in the prediction of Type 1 diabetes mellitus, with special reference to insulin autoantibodies. Diabetes Metab Res Rev 2005 21 : 395 415.
6. Winter WE, Harris N, Schatz D. Type 1 diabetes islet autoantibody markers. Diabetes Technol Ther 2002 4 : 817 839.
7. Pozzilli P, Manfrini S, Monetini L. Biochemical markers of Type 1 diabetes: clinical use. Scand J Clin Lab Invest Suppl 2001 235 : 38 44.
8. Batstra MR, Aanstoot HJ, Herbrink P. Prediction and diagnosis of Type 1 diabetes using beta-cell autoantibodies. Clin Lab 2001 47 : 497 507.
9. Solimena M. Vesicular autoantigens of Type 1 diabetes. Diabetes Metab Rev 1998 14 : 227 240.
10. Nepom GT. Glutamic acid decarboxylase and other autoantigens in IDDM. Curr Opin Immunol 1995 7 : 825 830.
11. Simsek S, Diamant M, Eekhoff EM, Heine RJ. Diabetes mellitus: simple classification and corresponding treatment. Ned Tijdschr Geneeskd 2006 150 : 1007 1012.
12. Irvine WJ, McCallum CJ, Gray RS, Campbell CJ, Duncan LJ, Farquhar JW et al. Pancreatic islet-cell antibodies in diabetes mellitus correlated with the duration and type of diabetes, coexistent autoimmune disease, and HLA type. Diabetes 1977 26 : 138 147.
13. Kobayashi T, Maruyama T, Shimada A, Kasuga A, Kanatsuka A, Takei I et al. Insulin intervention to preserve beta cells in slowly progressive insulin-dependent (Type 1) diabetes mellitus. Ann N Y Acad Sci 2002 958 : 117 130.
14. Juneja R, Palmer JP. Type 1 1/2 diabetes: myth or reality? Autoimmunity 1999 29 : 65 83.
15. Palmer JP, Hirsch IB. What's in a name: latent autoimmune diabetes of adults, Type 1.5, adult-onset, and Type 1 diabetes. Diabetes Care 2003 26 : 536 538.
16. Tuomi T, Groop LC, Zimmet PZ, Rowley MJ, Knowles W, Mackay IR. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease. Diabetes 1993 42 : 359 362.
17. Zimmet PZ, Tuomi T, Mackay IR, Rowley MJ, Knowles W, Cohen M et al. Latent autoimmune diabetes mellitus in adults (LADA): the role of antibodies to glutamic acid decarboxylase in diagnosis and prediction of insulin dependency. Diabet Med 1994 11 : 299 303.
18. Abiru N, Takino H, Yano M, Kawasaki E, Yamasaki H, Yamaguchi Y et al. Clinical evaluation of non-insulin-dependent diabetes mellitus patients with autoantibodies to glutamic acid decarboxylase. J Autoimmun 1996 9 : 683 688.
19. Landin-Olsson M, Nilsson KO, Lernmark A, Sundkvist G. Islet cell antibodies and fasting C-peptide predict insulin requirement at diagnosis of diabetes mellitus. Diabetologia 1990 33 : 561 568.
20. Niskanen LK, Karjalainen J, Sarlund H, Siitonen O, Uusitupa M. Five-year follow-up of islet cell antibodies in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetologia 1991 34 : 402 408.
21. Niskanen LK, Tuomi T, Karjalainen J, Groop LC, Uusitupa MI. GAD antibodies in NIDDM. Ten-year follow-up from the diagnosis. Diabetes Care 1995 18 : 1557 1565.
22. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A et al. Clinical and genetic characteristics of Type 2 diabetes with and without GAD antibodies. Diabetes 1999 48 : 150 157.
23. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR et al. UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in Type 2 diabetes. UK Prospective Diabetes Study Group. Lancet 1997 350 : 1288 1293.
24. Willis JA, Scott RS, Brown LJ, Forbes LV, Schmidli RS, Zimmet PZ et al. Islet cell antibodies and antibodies against glutamic acid decarboxylase in newly diagnosed adult-onset diabetes mellitus. Diabetes Res Clin Pract 1996 33 : 89 97.
25. Wroblewski M, Gottsater A, Lindgarde F, Fernlund P, Sundkvist G. Gender, autoantibodies, and obesity in newly diagnosed diabetic patients aged 40-75 years. Diabetes Care 1998 21 : 250 255.
26. Falorni A, Gambelunghe G, Forini F, Kassi G, Cosentino A, Candeloro P et al. Autoantibody recognition of COOH-terminal epitopes of GAD65 marks the risk for insulin requirement in adult-onset diabetes mellitus. J Clin Endocrinol Metab 2000 85 : 309 316.
27. Gambelunghe G, Forini F, Laureti S, Murdolo G, Toraldo G, Santeusanio F et al. Increased risk for endocrine autoimmunity in Italian Type 2 diabetic patients with GAD65 autoantibodies. Clin Endocrinol (Oxf) 2000 52 : 565 573.
28. Fukui M, Nakamura N, Nakano K, Sawada M, Aoji O, Obayashi H et al. Antibodies to GAD in elderly patients with previously diagnosed NIDDM. Diabetes Care 1998 21 : 675 676.
29. Pietropaolo M, Barinas-Mitchell E, Pietropaolo SL, Kuller LH, Trucco M. Evidence of islet cell autoimmunity in elderly patients with Type 2 diabetes. Diabetes 2000 49 : 32 38.
30. Davis TM, Wright AD, Mehta ZM, Cull CA, Stratton IM, Bottazzo GF et al. Islet autoantibodies in clinically diagnosed Type 2 diabetes: prevalence and relationship with metabolic control (UKPDS 70). Diabetologia 2005 48 : 695 702.
31. Kobayashi T, Nakanishi K, Sugimoto T, Itoh T, Murase T, Kosaka K et al. Maleness as risk factor for slowly progressive IDDM. Diabetes Care 1989 12 : 7 11.
32. Genovese S, Bazzigaluppi E, Goncalves D, Ciucci A, Cavallo MG, Purrello F et al. Clinical phenotype and beta-cell autoimmunity in Italian patients with adult-onset diabetes. Eur J Endocrinol 2006 154 : 441 447.
33. Falorni A, Brozzetti A. Diabetes-related antibodies in adult diabetic patients. Best Pract Res Clin Endocrinol Metab 2005 19 : 119 133.
34. Schernthaner G, Hink S, Kopp HP, Muzyka B, Streit G, Kroiss A. Progress in the characterization of slowly progressive autoimmune diabetes in adult patients (LADA or Type 1.5 diabetes). Exp Clin Endocrinol Diabetes 2001 109 : S94 108.
35. Desailloud R, Fajardy I, Vambergue A, Prevost G, Pigny P, Fontaine P. Autoimmune markers in slow Type 1 diabetes: confrontation to Type 1 diabetes. Diabetes Metab 2000 26 : 353 360.
36. Isomaa B, Almgren P, Tuomi T, Forsen B, Lahti K, Nissen M et al. Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001 24 : 683 689.
37. Romkens TE, Kusters GC, Netea MG, Netten PM. Prevalence and clinical characteristics of insulin-treated, anti-GAD-positive, Type 2 diabetic subjects in an outpatient clinical department of a Dutch teaching hospital. Neth J Med 2006 64 : 114 118.
38. Lohmann T, Kellner K, Verlohren HJ, Krug J, Steindorf J, Scherbaum WA et al. Titre and combination of ICA and autoantibodies to glutamic acid decarboxylase discriminate two clinically distinct types of latent autoimmune diabetes in adults (LADA). Diabetologia 2001 44 : 1005 1010.
39. Li X, Yang L, Zhou Z, Huang G, Yan X. Glutamic acid decarboxylase 65 autoantibody levels discriminate two subtypes of latent autoimmune diabetes in adults. Chin Med J (Engl) 2003 116 : 1728 1732.
40. Li X, Zhou ZG, Huang G, Yan X, Yang L, Chen XY et al. Optimal cutoff point of glutamate decarboxylase antibody titers in differentiating two subtypes of adult-onset latent autoimmune diabetes. Ann N Y Acad Sci 2004 1037 : 122 126.
41. Davis TM, Zimmet P, Davis WA, Bruce DG, Fida S, Mackay IR. Autoantibodies to glutamic acid decarboxylase in diabetic patients from a multi-ethnic Australian community: the Fremantle Diabetes Study. Diabet Med 2000 17 : 667 674.
42. Hamaguchi K, Kimura A, Kusuda Y, Yamashita T, Yasunami M, Takahasi M et al. Clinical and genetic characteristics of GAD-antibody positive patients initially diagnosed as having Type 2 diabetes. Diabetes Res Clin Pract 2004 66 : 163 171.
43. Takino H, Yamasaki H, Abiru N, Sera Y, Abe T, Kawasaki E et al. Antibodies to GAD in Japanese patients classified as Type 2 diabetes at diagnosis. High titre of GAD Ab is a predictive marker for early insulin treatment - report of west Japan (Kyushu, Yamaguchi, Osaka) study for GAD Ab(+) diabetes. Diabet Med 2002 19 : 730 734.
44. Harrison LC. Risk assessment, prediction and prevention of Type 1 diabetes. Pediatr Diabetes 2001 2 : 71 82.
45. Schranz DB, Bekris L, Landin-Olsson M, Torn C, Nilang A, Toll A et al. Newly diagnosed latent autoimmune diabetes in adults (LADA) is associated with low level glutamate decarboxylase (GAD65) and IA-2 autoantibodies. Diabetes Incidence Study in Sweden (DISS). Horm Metab Res 2000 32 : 133 138.
46. Bingley PJ, Christie MR, Bonifacio E, Bonfanti R, Shattock M, Fonte MT et al. Combined analysis of autoantibodies improves prediction of IDDM in islet cell antibody-positive relatives. Diabetes 1994 43 : 1304 1310.
47. Christie MR, Genovese S, Cassidy D, Bosi E, Brown TJ, Lai M et al. Antibodies to islet 37 k antigen, but not to glutamate decarboxylase, discriminate rapid progression to IDDM in endocrine autoimmunity. Diabetes 1994 43 : 1254 1259.
48. Gottsater A, Landin-Olsson M, Fernlund P, Lernmark A, Sundkvist G. Beta-cell function in relation to islet cell antibodies during the first 3 years after clinical diagnosis of diabetes in Type II diabetic patients. Diabetes Care 1993 16 : 902 910.
49. Borg H, Gottsater A, Landin-Olsson M, Fernlund P, Sundkvist G. High levels of antigen-specific islet antibodies predict future beta-cell failure in patients with onset of diabetes in adult age. J Clin Endocrinol Metab 2001 86 : 3032 3038.
50. Borg H, Gottsater A, Fernlund P, Sundkvist G. A 12-year prospective study of the relationship between islet antibodies and beta-cell function at and after the diagnosis in patients with adult-onset diabetes. Diabetes 2002 51 : 1754 1762.
51. Torn C, Landin-Olsson M, Lernmark A, Palmer JP, Arnqvist HJ, Blohme G et al. Prognostic factors for the course of beta cell function in autoimmune diabetes. J Clin Endocrinol Metab 2000 85 : 4619 4623.
52. Yang L, Zhou ZG, Huang G, Ouyang LL, Li X, Yan X. Six-year follow-up of pancreatic beta cell function in adults with latent autoimmune diabetes. World J Gastroenterol 2005 11 : 2900 2905.
53. Monge L, Bruno G, Pinach S, Grassi G, Maghenzani G, Dani F et al. A clinically orientated approach increases the efficiency of screening for latent autoimmune diabetes in adults (LADA) in a large clinic-based cohort of patients with diabetes onset over 50 years. Diabet Med 2004 21 : 456 459.
54. Kasuga A, Maruyama T, Nakamoto S, Ozawa Y, Suzuki Y, Saruta T. High-titer autoantibodies against glutamic acid decarboxylase plus autoantibodies against insulin and IA-2 predicts insulin requirement in adult diabetic patients. J Autoimmun 1999 12 : 131 135.
55. Grasso YZ, Reddy SK, Rosenfeld CR, Hussein WI, Hoogwerf BJ, Faiman C et al. Autoantibodies to IA-2 and GAD65 in patients with Type 2 diabetes mellitus of varied duration: prevalence and correlation with clinical features. Endocr Pract 2001 7 : 339 345.
56. Kobayashi T, Tanaka S, Okubo M, Nakanishi K, Murase T, Lernmark A. Unique epitopes of glutamic acid decarboxylase autoantibodies in slowly progressive Type 1 diabetes. J Clin Endocrinol Metab 2003 88 : 4768 4775.
57. Bell DS. Diabetes mellitus and coronary artery disease. J Cardiovasc Risk 1997 4 : 83 90.
58. Alexander CM, Landsman PB, Teutsch SM. Diabetes mellitus, impaired fasting glucose, atherosclerotic risk factors, and prevalence of coronary heart disease. Am J Cardiol 2000 86 : 897 902.
59. Ziegler D, Gries FA, Muhlen H, Rathmann W, Spuler M, Lessmann F. Prevalence and clinical correlates of cardiovascular autonomic and peripheral diabetic neuropathy in patients attending diabetes centers. The Diacan Multicenter Study Group. Diabete Metab 1993 19 : 143 151.
60. de Wytt CN, Jackson RV, Hockings GI, Joyner JM, Strakosch CR. Polyneuropathy in Australian outpatients with Type II diabetes mellitus. J Diabetes Complications 1999 13 : 74 78.
61. Weerasuriya N, Siribaddana S, Wijeweera I, Dissanayeka A, Wijesekera J, Fernando DJ. The prevalence of peripheral neuropathy in newly diagnosed patients with non-insulin-dependent diabetes mellitus. Ceylon Med J 1998 43 : 19 21.
62. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI. Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with Type 2 diabetes in North America and Europe. Diabetes 2004 53 : 3193 3200.
63. Juneja R, Hirsch IB, Naik RG, Brooks-Worrell BM, Greenbaum CJ, Palmer JP. Islet cell antibodies and glutamic acid decarboxylase antibodies, but not the clinical phenotype, help to identify Type 1(1/2) diabetes in patients presenting with Type 2 diabetes. Metabolism 2001 50 : 1008 1013.
64. Rolandsson O, Hagg E, Hampe C, Sullivan EP Jr., Nilsson M, Jansson G et al. Glutamate decarboxylase (GAD65) and tyrosine phosphatase-like protein (IA-2) autoantibodies index in a regional population is related to glucose intolerance and body mass index. Diabetologia 1999 42 : 555 559.
65. Schiel R, Muller UA. GAD autoantibodies in a selection-free population of insulin-treated diabetic patients: indicator of a high prevalence of LADA? Diabetes Res Clin Pract 2000 49 : 33 40.
66. Castleden HA, Shields B, Bingley PJ, Williams AJ, Sampson M, Walker M et al. GAD antibodies in probands and their relatives in a cohort clinically selected for Type 2 diabetes. Diabet Med 2006 23 : 834 838.
67. Magliano DJ, Shaw JE, Zimmet PZ. How to best define the metabolic syndrome. Ann Med 2006 38 : 34 41.
68. Gogia A, Agarwal PK. Metabolic syndrome. Indian J Med Sci 2006 60 : 72 81.
69. Zimmet P, Magliano D, Matsuzawa Y, Alberti G, Shaw J. The metabolic syndrome: a global public health problem and a new definition. J Atheroscler Thromb 2005 12 : 295 300.
70. Reisin E, Alpert MA. Definition of the metabolic syndrome: current proposals and controversies. Am J Med Sci 2005 330 : 269 272.
71. Liberopoulos EN, Mikhailidis DP, Elisaf MS. Diagnosis and management of the metabolic syndrome in obesity. Obes Rev 2005 6 : 283 296.
72. De Block CE, De Leeuw IH, Vertommen JJ, Rooman RP, Du Caju MV, Van Campenhout CM et al. Beta-cell, thyroid, gastric, adrenal and coeliac autoimmunity and HLA-DQ types in Type 1 diabetes. Clin Exp Immunol 2001 126 : 236 241.
73. Liu E, Eisenbarth GS. Type 1A diabetes mellitus-associated autoimmunity. Endocrinol Metab Clin North Am 2002 31 : 391 410.
74. Barova H, Perusicova J, Hill M, Sterzl I, Vondra K, Masek Z. Anti-GAD-positive patients with Type 1 diabetes mellitus have higher prevalence of autoimmune thyroiditis than anti-GAD-negative patients with Type 1 and Type 2 diabetes mellitus. Physiol Res 2004 53 : 279 286.
75. Kučera P, Novakova D, Behanova M, Novak J, Tlaskalova-Hogenova H, Andel M. Gliadin, endomysial and thyroid antibodies in patients with latent autoimmune diabetes of adults (LADA). Clin Exp Immunol 2003 133 : 139 143.
76. Schober E, Granditsch G. IDDM and celiac disease. Diabetes Care 1994 17 : 1549 1550.
77. Rewers M, Liu E, Simmons J, Redondo MJ, Hoffenberg EJ. Celiac disease associated with Type 1 diabetes mellitus. Endocrinol Metab Clin North Am 2004 33 : 197 214, xi.
78. Schuppan D, Hahn EG. Celiac disease and its link to Type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2001 14 : 597 605.
79. Holmes GK. Screening for coeliac disease in Type 1 diabetes. Arch Dis Child 2002 87 : 495 498.
80. Davies JL, Kawaguchi Y, Bennett ST, Copeman JB, Cordell HJ, Pritchard LE et al. A genome-wide search for human Type 1 diabetes susceptibility genes. Nature 1994 371 : 130 136.
81. Tisch R, McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996 85 : 291 297.
82. Undlien DE, Friede T, Rammensee HG, Joner G, Dahl-Jorgensen K, Sovik O et al. HLA-encoded genetic predisposition in IDDM: DR4 subtypes may be associated with different degrees of protection. Diabetes 1997 46 : 143 149.
83. Pugliese A, Gianani R, Moromisato R, Awdeh ZL, Alper CA, Erlich HA et al. HLA-DQB1*0602 is associated with dominant protection from diabetes even among islet cell antibody-positive first-degree relatives of patients with IDDM. Diabetes 1995 44 : 608 613.
84. Kockum I, Lernmark A, Dahlquist G, Falorni A, Hagopian WA, Landin-Olsson M et al. Genetic and immunological findings in patients with newly diagnosed insulin-dependent diabetes mellitus. The Swedish Childhood Diabetes Study Group and The Diabetes Incidence in Sweden Study (DISS) Group. Horm Metab Res 1996 28 : 344 347.
85. Takeda H, Kawasaki E, Shimizu I, Konoue E, Fujiyama M, Murao S et al. Clinical, autoimmune, and genetic characteristics of adult-onset diabetic patients with GAD autoantibodies in Japan (Ehime Study). Diabetes Care 2002 25 : 995 1001.
86. Gale EA. Latent autoimmune diabetes in adults: a guide for the perplexed. Diabetologia 2005 48 : 2195 2199.
87. Leslie RD, Williams R, Pozzilli P. Clinical review: Type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006 91 : 1654 1659.
88. Hoppener JW, Lips CJ. Role of islet amyloid in Type 2 diabetes mellitus. Int J Biochem Cell Biol 2006 38 : 726 736.
89. Mohan V, Deepa R, Bhatia E, Singh AK, Hitman GA, Zimmet PZ et al. Antibodies to pancreatic islet cell antigens in diabetes seen in Southern India with particular reference to fibrocalculous pancreatic diabetes. Diabet Med 1998 15 : 156 159.
90. Singh AK, Bhatia E, Dabadghao P, Bhatia V, Gellert SA, Colman PG. Role of islet autoimmunity in the aetiology of different clinical subtypes of diabetes mellitus in young north Indians. Diabet Med 2000 17 : 275 280.
91. Dabadghao P, Bhatia E, Bhatia V, Jayaraj K, Colman PG. Islet-cell antibodies in malnutrition-related diabetes mellitus from north India. Diabetes Res Clin Pract 1996 34 : 73 78.
92. Tandhanand-Banchuin N, Kespichayawatana W, Vannasaeng S, Sarasombath S. A study of cell-mediated immune response to pancreatic antigens in patients with fibrocalculous pancreatic diabetes. Asian Pac J Allergy Immunol 1996 14 : 91 97.
93. Tandhanand-Banchuin N, Kespichayawatana W, Vannasaeng S, Banchuin C, Laohapand T, Panpimarnmas S et al. Presence of autoimmunity to pancreatic antigens in a patient with fibrocalculous pancreatic diabetes. Diabetes Res Clin Pract 1992 18 : 17 21.
94. Mire-Sluis AR, Das RG, Lernmark Å. The World Health Organization International Collaborative Study for Islet Cell Antibodies. Diabetologia 2000 43 : 1282 1292.
95. Bingley PJ, Bonifacio E, Mueller PW. Diabetes antibody standardization program: first assay proficiency evaluation. Diabetes 2003 52 : 1128 1136.